PHGDH and cancer: The combination of perhexiline with a PHGDH small molecule inhibitor (NCT-503) resulted in significant synergistic cell death in vitro and in vivo, providing preclinical justification for a dual metabolism-based combination therapy for PHGDH-high cancers.